Navigation Links
KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
Date:3/25/2008

ST. LOUIS, March 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVA/KVB), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced the filing of its fiscal 2007 Form 10-K with the Securities and Exchange Commission.

The filing includes restatements of previously reported results for fiscal years 1995 through 2006. In addition, the Company filed a Form 10-QA for the quarter ended June 30, 2006 and Form 10-Q's for the quarters ended September 30, 2006 and December 31, 2006. These filings complete the Company's previously announced restatement of financial results. The financial statements for fiscal 2007 included in the Form 10-K filed with the Securities and Exchange Commission are consistent with the previously reported unaudited financial information which was detailed in a press release dated February 15, 2008.

The Company is currently in the process of completing its Form 10-Q's for the fiscal quarters ended June 30, 2007, September 30, 2007 and December 31, 2007. The filing of the fiscal 2007 10-K brings the Company into compliance with the annual reporting conditions for continued trading on the New York Stock Exchange. However, KV will remain on the NYSE late filer list until its fiscal 2008 quarterly filings are completed.

The Company's filings have been delayed due to the previously reported investigation by a Special Committee of independent members of the Board of Directors into the Company's former stock option grant practices. The investigation concluded that no employee, officer or director of the Company engaged in any intentional wrongdoing or was aware that the Company's policies and procedures for granting and accounting for stock options were materially non-compliant with U.S. Generally Accepted Accounting Principles. The investigation also found no intentio
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
2. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
3. Sales and Marketing Effectiveness in Pharmaceutical Companies Increases Brand Performance
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
7. Alseres Pharmaceuticals, Inc. Raises $5 Million
8. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
11. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
(Date:9/2/2015)... , Sept. 2, 2015  Research and ... of the "An Introduction to the Medical ... conference to their offering. ... European medical device legislation. It will explain the ... of Notified Bodies, how to choose one and ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ... new report "Drug Delivery in Central Nervous ... to their offering. Advances in ... have opened new avenues and possibilities for improved ... transport systems, enzymes, and receptors that control the ...
(Date:9/2/2015)... , Sept. 2, 2015  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, announced today ... its multi-center Phase 1/2a clinical trial of AGT-181 ... I). AGT-181 is an investigational ... MPS I. The most severe form of MPS ...
Breaking Medicine Technology:Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... BEIJING and NEW YORK, Oct. 6, 2011 /PRNewswire-Asia-FirstCall/ -- ... the "Company"), one of the leading plasma-based biopharmaceutical companies ... changes in its board of directors. On ... positions as a director of China Biologic, a member ...
... ( www.celsyalife.com ) ... Celsya™ website ( www.celsyalife.com ), a comprehensive online and mobile ... End Alzheimer,s" in Los Angeles on Sunday, October 9, 2011. ... Alzheimer,s, to live better, healthier, and be safer. ...
Cached Medicine Technology:China Biologic Announces Changes in Directors 2China Biologic Announces Changes in Directors 3China Biologic Announces Changes in Directors 4CelsyaLife.com Set to Launch at "Walk to End Alzheimer's" 2
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: